Key Points Interested in OnKure Therapeutics, Inc.? Here are five stocks we like better. OnKure Therapeutics is advancing two ...
NEW YORK & GENEVA--(BUSINESS WIRE)--Neurosterix, a biopharmaceutical company dedicated to the development of allosteric modulator therapeutics for underserved neurological disorders, launched today ...
WALTHAM, Mass.--(BUSINESS WIRE)--Ensem Therapeutics, Inc. (ENSEM), a pioneering drug discovery and development company that leverages its unique Kinetic Ensemble® platform to advance innovative small ...
OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision ...
Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with ...
Researchers from China Pharmaceutical University reported the discovery and preclinical characterization of allosteric inhibitors of Src homology-2-containing protein tyrosine phosphatase 2 (SHP2) as ...
Atomwise Inc. reported the development and preclinical evaluation data of ATMW-DC, a novel orally available allosteric inhibitor of TYK2 developed using Atomwise’s drug discovery platform Atomnet, for ...
SOUTH SAN FRANCISCO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Nura Bio Inc. (Nura Bio), a clinical-stage biopharmaceutical company developing neuroprotective small molecule therapies, today announced ...
A novel agent, para-toluenesulfonamide, for the management of malignant pleural effusions. Matching-adjusted indirect comparison of bireociclib plus fulvestrant versus abemaciclib plus fulvestrant as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results